Aclaris Therapeutics
Develops immunology drug candidates through biologics, kinase inhibitors, and discovery services.
Something off on this page? Send us feedback.
Profile
Develops immuno-inflammatory therapies around licensed biologics, oral kinase inhibitors, and the KINect discovery platform. Revenue comes from intellectual-property licensing and laboratory services while the main business remains clinical development rather than approved-product sales.
Focuses on immuno-inflammatory diseases with a clinical pipeline built around bosakitug, ATI-052, ATI-2138, ATI-9494, and KINect discovery work. The portfolio mixes licensed biologics with oral kinase inhibitors, while laboratory services and intellectual-property licensing provide the current revenue base.
Operates from Pennsylvania as a pre-commercial biotech without an owned commercial sales force. Earlier dermatology products such as ESKATA and RHOFADE gave way to a refocus on immunology research and partner-led development after the commercial dermatology buildout was discontinued.
Execution depends on clinical trial progress, third-party partners, and outside manufacturing for product candidates and trial materials. Competitive pressure comes from other immunology programs targeting overlapping pathways.
Company facts
Key statistics
Year to date +109% · Average volume (30d) 1.8M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Target |
|---|---|---|---|---|---|
| May 5, 2026 | Piper Sandler | Reiterate | Overweight | $11 | |
| May 5, 2026 | Guggenheim | Target | $12 | ||
| Apr 29, 2026 | Wedbush | Reiterate | Outperform | $10 | |
| Apr 16, 2026 | UBS | Target | $10 | ||
| Jan 30, 2026 | Craig-Hallum | Target | $10 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026Q2 FY26 | −$0.16 | −$0.15 | +6.3% | $1.4M | $1.6M | +17.8% | −4.25% |
| May 7, 2026Q1 FY26 | −$0.16 | −$0.15 | +6.3% | $1.3M | $2.0M | +51.0% | +1.44% |
| Feb 26, 2026Q4 FY25 | −$0.15 | −$0.16 | −6.7% | $2.1M | $1.3M | −37.5% | −8.31% |
| Nov 6, 2025Q3 FY25 | −$0.13 | −$0.12 | +7.7% | $2.1M | $3.3M | +59.3% | +2.20% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $1.5M | $1.8M | $3.3M | $1.3M | $2.0M | $1.6M | |
| Gross profit | $949.0K | −$73.0K | $2.8M | $2.1M | $1.6M | $1.4M | |
| Operating income | −$18.1M | −$18.4M | −$17.1M | −$22.7M | −$22.2M | −$24.2M | |
| Net income | −$15.1M | −$15.4M | −$14.6M | −$19.8M | −$19.8M | −$21.5M | |
| Diluted EPS | −$0.12 | −$0.13 | −$0.12 | −$0.16 | −$0.15 | −$0.15 | |
| Gross margin | 65.2% | -4.1% | 83.7% | 162.0% | 80.2% | 85.8% | |
| Operating margin | -1,242.9% | -1,035.9% | -519.8% | -1,755.5% | -1,111.8% | -1,487.9% |
Fiscal years (4-quarter sums)FY21 $6.8M · FY22 $29.8M · FY23 $31.2M · FY24 $18.7M · FY25 $7.8M
Revenue by product · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $91.6M · Total debt $0 · Total assets $179.7M · Shareholders' equity $124.6M
Dividends
No dividends on record.
Ownership
Shares outstanding 139.66M · Float 113.14M · 81.0% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BML Investment Partners, L.P. | 13.95M | 9.90% | 13G | Apr 27, 2026 |
| Leonard Braden Michael · 10 percent owner | 13.95M | 9.99% | Form 4 | Apr 27, 2026 |
| Ra Capital Management, L.P. | 12.72M | 9.11% | 13F | Aug 14, 2026 |
| BML Capital Management, LLC | 11.98M | 8.57% | 13F | Aug 7, 2026 |
| Biosion, Inc. | 11.28M | 9.40% | 13G | Jan 9, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Apr 23, 2026 | Braden Michael Leonard | 10 percent owner | −300,000 | $4.53 |
Peers
- Sanofi (ADR)
Dupixent and lunsekimig pressure type-2 immunology programs
- Pfizer
Type-2 trispecific antibodies plus marketed AD JAK exposure
- Regeneron
Dupixent co-owner with deep type-2 inflammation reach
- AstraZeneca (ADR)
Tezspire anchors approved anti-TSLP asthma competition
- Upstream Bio
Verekitug targets the TSLP receptor in respiratory disease
- Corvus Pharmaceuticals
Selective ITK inhibition overlaps ATI-2138 kinase strategy
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Aclaris Therapeutics | $6.01 | 0.00% | $839.4M | — | — | 102.1 | −8.3% |
| Sanofi (ADR) | $44.83 | +0.02% | $107.62B | 78.9 | — | 1.9 | +11.2% |
| Pfizer | $27.95 | −0.04% | $159.36B | 36.9 | 10.0 | 2.5 | +2.6% |
| Regeneron | $793.21 | −0.11% | $81.82B | 19.6 | 13.1 | 5.3 | +16.7% |
| AstraZeneca (ADR) | $161.79 | −0.55% | $252.33B | 24.4 | 15.2 | 4.1 | +6.4% |
| Upstream Bio | $6.69 | +0.15% | $364.1M | — | — | 115.3 | −17.5% |
| Corvus Pharmaceuticals | $14.16 | +0.11% | $1.19B | — | — | — | — |
| Median | 30.7 | 13.1 | 4.1 | +6.4% |